Kenemans P, Bosman A
Department of Obstetrics and Gynaecology, Free University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Best Pract Res Clin Endocrinol Metab. 2003 Mar;17(1):123-37. doi: 10.1016/s1521-690x(02)00084-2.
From the introduction of post-menopausal hormone replacement therapy (HRT) there has been great concern that HRT could possibly increase the risk of breast cancer. Prolonged exposure to endogenous oestrogens undeniably increases the risk of breast cancer. Questions that are important and until now only partly answered, are the following. Are oestrogens tumour promoters, as they induce mitosis, lead to proliferation and, therefore, accelerated growth of clinically occult pre-existing tumours? In addition to this, are they genotoxic mutagenic carcinogens, or could they initiate tumours by way of accumulation of incessant DNA-replication damage mechanism? Opinions vary as to the effect of the addition of a progestogen. There is a multitude of different progestogens which could bind with differing affinity to progesterone receptor PR-A or PR-B, and which have different physiological functions via differential gene regulation. The action of a progestogen on the oestrogen-induced cellular mitotic activity could be synergistic or antagonistic (by different pathways: oestrogen receptor downregulation, activating of metabolic pathways within the breast or stimulation of apoptosis)? Over 60 observational studies and two randomized trials provide evidence that the small but significant increase in risk appears with long-term current post-menopausal hormone use. The addition of a progestogen does not decrease the risk as seen with oestrogens alone and might increase the risk further. It is not clear whether there is a difference in risk with sequentially combined versus continuously combined HRT. Many questions nevertheless still remain. Is the risk increase limited to lean women only? What about risk-modifying factors such as alcohol use and a positive family history for breast cancer? Are tumours detected under HRT less aggressive, is there a better prognosis and is the mortality not increased while morbidity is? And is HRT contraindicated for women with a positive family history for breast cancer or in those women who have been treated for breast cancer? And finally, are there alternative options for these women?
自绝经后激素替代疗法(HRT)引入以来,人们一直非常担心HRT可能会增加患乳腺癌的风险。不可否认,长期暴露于内源性雌激素会增加患乳腺癌的风险。以下是一些重要且至今仍未完全解答的问题。雌激素是肿瘤促进剂吗?因为它们会诱导有丝分裂,导致细胞增殖,从而加速临床隐匿的现有肿瘤的生长。除此之外,它们是基因毒性诱变致癌物吗?或者它们是否会通过持续的DNA复制损伤机制的积累引发肿瘤?关于添加孕激素的效果,观点不一。有多种不同的孕激素,它们与孕激素受体PR - A或PR - B的结合亲和力不同,并且通过不同的基因调控具有不同的生理功能。孕激素对雌激素诱导的细胞有丝分裂活性的作用可能是协同的或拮抗的(通过不同途径:雌激素受体下调、激活乳腺内的代谢途径或刺激细胞凋亡)?超过60项观察性研究和两项随机试验提供了证据,表明绝经后长期使用激素会使风险虽小但显著增加。添加孕激素并不会像单独使用雌激素那样降低风险,反而可能会进一步增加风险。目前尚不清楚序贯联合与连续联合HRT在风险上是否存在差异。然而,许多问题仍然存在。风险增加是否仅局限于瘦女性?像饮酒和乳腺癌家族史阳性等风险修正因素又如何呢?在HRT期间检测到的肿瘤侵袭性较小吗?预后会更好吗?发病率增加的同时死亡率不会增加吗?对于乳腺癌家族史阳性的女性或曾接受过乳腺癌治疗的女性,HRT是否禁忌?最后,这些女性有其他选择吗?